Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes: A randomized, open-label trial

OBJECTIVE: To assess the efficacy and safety of switching from sitagliptin to liraglutide in metformin-treated adults with type 2 diabetes. RESEARCH DESIGN AND METHODS: In an open-label trial, participants randomized to receive either liraglutide (1.2 or 1.8 mg/day) or sitagliptin (100 mg/day), each...

Descripción completa

Detalles Bibliográficos
Autores principales: Pratley, Richard E., Nauck, Michael A., Bailey, Timothy, Montanya, Eduard, Filetti, Sebastiano, Garber, Alan J., Thomsen, Anne B., Furber, Sabina, Davies, Melanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3447855/
https://www.ncbi.nlm.nih.gov/pubmed/22851600
http://dx.doi.org/10.2337/dc11-2113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3447855/
https://www.ncbi.nlm.nih.gov/pubmed/22851600
http://dx.doi.org/10.2337/dc11-2113

Ejemplares similares